CARDIOVASCULAR EVENTS IN PATIENTS WITH FABRY DISEASE: NATURAL HISTORY DATA FROM THE FABRY REGISTRY  by Patel, Manesh R. et al.
A30.E291
JACC March 9, 2010
Volume 55, issue 10A
 CARDIAC FUNCTION AND HEART FAILURE 
CARDIOVASCULAR EVENTS IN PATIENTS WITH FABRY DISEASE: NATURAL HISTORY DATA FROM THE 
FABRY REGISTRY
ACC Poster Contributions
Georgia World Congress Center, Hall B5
Monday, March 15, 2010, 3:30 p.m.-4:30 p.m.
Session Title: Genetics and Cardiomyopathies II
Abstract Category: Cardiomyopathies/Myocarditis/Pericardial Disease
Presentation Number: 1175-35
Authors: Manesh R. Patel, Franco Cecchi, Marta Cizmarik, Ilkka Kantola, Ales Linhart, Kathy Nicholls, Jorg Strotmann, Jose Tallaj, Thi Chien Tran, 
Michael L. West, Ademola Abiose, Duke University, Durham, NC
Background: Fabry disease, a disorder caused by deficiency of alpha-galactosidase A activity, is associated with cardiovascular dysfunction. 
However, the incidence of cardiovascular events (CV events) and the natural history of cardiovascular complications in Fabry disease are not well 
characterized.
Methods: Various CV events were analyzed among 2869 Fabry Registry patients during the natural history period (i.e., before enzyme replacement 
therapy). CV events included myocardial infarction, congestive heart failure, any arrhythmia, angina pectoris, or an invasive cardiac procedure.
Results: A total of 487 patients (17%) experienced CV events, including 282 of 1424 males (20%) and 205 of 1445 females (14%). Median age 
at first CV event was 42.8 in males and 49.1 in females; see age distribution below. One hundred sixty-nine of 1424 males (12%) and 112 of 1445 
females (8%) reported arrhythmia as their first CV event. Congestive heart failure incidence was substantially higher in Fabry Registry patients than in 
the general US population. Among various risk factors evaluated, hypertension was most strongly associated with the occurrence of CV events (7.2-
fold in males and 9.6-fold in females), followed by smoking, LV hypertrophy, older age at diagnosis, and lower estimated glomerular filtration rate.
Conclusions: CV events are common in Fabry patients who have not received enzyme replacement therapy. All patients with Fabry disease should 
be monitored for possible cardiovascular risk factors.
